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sion of cardiovascular calcification, including the type of
calcium-containing binder (calcium acetate is twice as effec-
tive as calcium carbonate yet contains half the amount ofTo the Editor: In their unblinded study of vascular
elemental calcium), dialysate calcium, vitamin D dose,calcification in dialysis patients, Chertow et al combine
and lipid levels. Did sevelamer-treated patients receive
results from patients receiving calcium acetate with those
a nighttime calcium supplement or increased dialysate
from patients receiving calcium carbonate. Use of these calcium to prevent hypocalcemia? Were there differences
calcium salts interchangeably in studies is not appro- in progression of calcification between calcium acetate-
priate since calcium acetate is a more potent phosphate and calcium carbonate-treated patients? Since vitamin D
binder with less calcium absorption [1]. This can be seen increases calcium absorption and hypercalcemia risk, and
in the study of Chertow et al by the differences in re- may itself predispose to cardiovascular calcification [2],
quired doses. If the hypothesis concerning the relation- Chertow et al should have controlled for vitamin D use.
ship of calcification to oral calcium advanced by the In the calcium-treated patients, low-density lipoprotein
authors is correct, it would be very useful to see the (LDL) cholesterol should have been controlled to an equiv-
study results analyzed for each salt separately in order alent level with 3-hydroxy-3-methylglutaryl coenzyme A
to test for dose response effects. This is particularly im- (HMG-CoA) reductase inhibitors. Given failure to ade-
portant because the average daily dose of calcium acetate quately control other important variables, this study by
required by patients in this study was nearly equivalent Chertow et al clearly does not establish a causal relation-
to the USRDA for calcium. ship between cardiovascular calcification and possible
It is likely that the sevelamer patients received supple- calcium loading from calcium-containing binders. We,
therefore, believe that this study by Chertow et al doesmental calcium (as shown by the absence of change in se-
not justify preferential use of the considerably more ex-rum calcium levels over the course of the year and that
pensive phosphate binder sevelamer hydrochloride. Fi-some also experienced hypercalcemia). Traditionally, in
nally, could the metabolic acidosis in this and other stud-studies of sevelamer, 1 gram of supplemental calcium is
ies be explained by an acid load provided by sevelameroften given to prevent hypocalcemia [2]. This dose is
hydrochloride [3].nearly equivalent to the calcium dose utilized by Cher-
tow et al in the calcium treatment arm. Clearly, there was
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